

Key Points to Keep in Mind



It is ***very easy*** to know what the blood plasma profile for a once-a-day bupropion product would look like.



It is ***very difficult*** to create a dosage form that achieves the once-a-day blood plasma profile.



Andrx attempts at making a once-a-day product ***solely used pellets.***



GSK's product doesn't use pellets.

Variability in Blood Plasma Parameters Results from:

- ▶ **THE DRUG** used in testing
- ▶ **THE DOSAGE FORM**
- ▶ **DIFFERENCES BETWEEN** different individuals tested
- ▶ **DIFFERENCES WITHIN** the same individual studied at different times
- ▶ **DIFFERENCES** in how the study is designed and carried out
- ▶ **DIFFERENCES** in testing conditions
- ▶ **DIFFERENCES** in measurement techniques for blood drug levels

Drug Delivery

Multiple Drug Administration:

Repeated administration of immediate release dosage form is needed to maintain therapeutic blood plasma levels





Exhibit ADH

Drug Delivery

Single Drug Administration:

Maintain desired drug level for specified time periods



Route of Administration of Drugs

- ▶ Oral
- ▶ Injection
- ▶ Intravenous
- ▶ Transdermal
- ▶ Inhaled
- ▶ Suppository
- ▶ Topical

Many Factors Influence the Route of Administration Chosen for a Particular Drug

- ▶ The chemical and physical properties of the drug itself
 - solubility
 - permeability
 - stability
- ▶ Location of the target organs or tissues
- ▶ Ability to manufacture dosage form
- ▶ Ability to control release
- ▶ Patient convenience

**In General,
Oral Administration
Is Preferred for
Patient Convenience**

TYPES OF ORAL DOSAGE FORMS:

- ▶ Tablet
- ▶ Capsule
- ▶ Gel capsule
- ▶ Pellets
- ▶ Syrup or solution
- ▶ Powder
- ▶ Liquid suspension
- ▶ Film coated tablet
- ▶ Hybrid tablet

**In Order for a Drug
That Is Given Orally
to Work, the
Active Ingredient:**


- ▶ ***MUST*** be released from the formulation

- ▶ ***MUST*** dissolve in the GI tract

- ▶ ***MUST*** be absorbed into the bloodstream

- ▶ ***MUST*** distribute itself to the target organs or tissues

Drug Absorption and Elimination



1

Release



2

Absorption




3

Distribution



4

Metabolism/Excretion



Blood Plasma Profiles Are Used to Measure the Effectiveness of a Drug




Exhibit ADD

Definitions of Pharmacokinetic (PK) Parameters

C_{max}

Represents the maximum concentration of drug found in the blood plasma of a patient to whom the dosage form has been administered.




Exhibit ADE

Definitions of Pharmacokinetic (PK) Parameters

T_{max}

The time from administration at which the plasma concentration achieves C_{max} .





Exhibit ADF

Definitions of Pharmacokinetic (PK) Parameters

AUC

AREA UNDER THE CURVE

The total amount of drug available over time in the blood to achieve the desired therapeutic effect.



Bioavailability

AUC

AREA UNDER THE CURVE

A measure of the **bioavailability** of the active drug from the dosage form.





Exhibit ADV

pH in the Digestive (GI) Tract



What Is pH?

A measure of whether something is acidic or basic



What Is pH?

A measure of whether something is acidic or basic



What Is pH?

A measure of whether something is acidic or basic



What Is pH?


A measure of whether something is acidic or basic




GI Tract Transit Time

GENERALLY TAKES 24 HOURS


LEAVES
STOMACH WITHIN:
1–6 HOURS



RESIDES IN
SMALL INTESTINE:
3–5 HOURS



RESIDES IN
LARGE INTESTINE:
5–7 HOURS



Dosage Form Disclosed in the Andrx '708 Patent


ANDRX '708 PATENT

A multi-pellet dosage form comprised of two or three types of pellets designed to be released into a different region of the digestive tract at a different time as a function of pH.

See '708 Patent Col. 6: 37 – 49

Sustained Release Pellets

Bupropion
Inert Core
Water Insoluble Polymer Coating



Drug released at pH of about 4.8 and lower

Enteric Coated Pellets


Bupropion
Inert Core
Enteric Coating



Drug released at pH of about 7.0 and above

Instant Release Pellets

Bupropion
Inert Core




No coating — Drug released immediately

Dosage Form Claimed in the Andrx '708 Patent


ANDRX '708 PATENT

Preferred Embodiment




ANDRX '708 PATENT



Alternate Embodiment




Dosage Form Claimed in the Andrx '708 Patent



OUTER COATING
*of capsule dissolves
in the stomach*



Dosage Form Claimed in the Andrx '708 Patent





TWO TYPES OF PELLETS
are released
in the stomach

**FIRST TYPE
OF PELLETS**

**SECOND TYPE
OF PELLETS**


Dosage Form Claimed in the Andrx '708 Patent



Dosage Form Claimed in the Andrx '708 Patent



SECOND TYPE OF PELLETT
releases bupropion
in the ileum



The Andrx '708 Patent IS OBVIOUS

ANDRX '708 PATENT	
CLAIM 1	OBVIOUS OVER PRIOR ART?
A once daily dosage form comprising 150 mg of an [sic] bupropion or salt of bupropion,	?
said dosage form providing an in vivo plasma profile selected from:	?
(a) Mean T_{max} of about 5 or more hours	
(b) Mean C_{max} of less than about 90 ng/ml, and	?
(c) Mean AUC_{0-120h} of more than about 350 (ng-h)ml.	?

The Andrx '708 Patent IS OBVIOUS

ANDRX '708 PATENT	
CLAIM 1	OBVIOUS OVER PRIOR ART?
A once daily dosage form comprising 150 mg of an [sic] bupropion or salt of bupropion,	YES GSK's '798 Patent: "With the tablets of this invention it is now possible to <i>dose one...times per day....</i> " <small>Col 1: 60 – 62</small>
said dosage form providing an in vivo plasma profile selected from:	?
(a) Mean T_{max} of about 5 or more hours	
(b) Mean C_{max} of less than about 90 ng/ml, and	?
(c) Mean AUC_{0-120h} of more than about 350 (ng-h)ml.	?

The Andrx '708 Patent IS OBVIOUS

ANDRX '708 PATENT		
CLAIM 1	OBVIOUS OVER PRIOR ART?	
A once daily dosage form comprising 150 mg of an [sic] bupropion or salt of bupropion,	YES	GSK's '798 Patent: "With the tablets of this invention it is now possible to <i>dose one...times per day....</i>" <i>Col 1: 60 – 62</i>
said dosage form providing an in vivo plasma profile selected from: (a) Mean T_{max} of about 5 or more hours	YES	It was obvious to one skilled in the art to increase T_{max} from the 2.5 hours claimed in GSK's '798 patent to achieve a one-a-day dosage form. <i>See Cheng Dep. Tr. at 141: 8 – 21</i>
(b) Mean C_{max} of less than about 90 ng/ml, and	?	
(c) Mean AUC_{0-120h} of more than about 350 (ng-h)ml.	?	

The Andrx '708 Patent IS OBVIOUS


ANDRX '708 PATENT		
CLAIM 1	OBVIOUS OVER PRIOR ART?	
A once daily dosage form comprising 150 mg of an [sic] bupropion or salt of bupropion,	YES	<p>GSK's '798 Patent:</p> <p>“With the tablets of this invention it is now possible to dose one...times per day....”</p> <p><i>Col 1: 60 – 62</i></p>
<p>said dosage form providing an in vivo plasma profile selected from:</p> <p>(a) Mean T_{max} of about 5 or more hours</p>	YES	<p>It was obvious to one skilled in the art to increase T_{max} from the 2.5 hours claimed in GSK's '798 patent to achieve a one-a-day dosage form.</p> <p><i>See Cheng Dep. Tr. at 141: 8 – 21</i></p>
<p>(b) Mean C_{max} of less than about 90 ng/ml, and</p>	YES	<p>Figure 6 of GSK's '798 patent discloses a mean C_{max} of about 85 ng/ml.</p>
<p>(c) Mean AUC_{0-120h} of more than about 350 (ng-h)ml.</p>	?	

The Andrx '708 Patent IS OBVIOUS

ANDRX '708 PATENT		
CLAIM 1	OBVIOUS OVER PRIOR ART?	
A once daily dosage form comprising 150 mg of an [sic] bupropion or salt of bupropion,	YES	GSK's '798 Patent: "With the tablets of this invention it is now possible to dose one...times per day.... " <i>Col 1: 60 – 62</i>
said dosage form providing an in vivo plasma profile selected from: (a) Mean T_{max} of about 5 or more hours	YES	It was obvious to one skilled in the art to increase T_{max} from the 2.5 hours claimed in GSK's '798 patent to achieve a one-a-day dosage form. <i>See Cheng Dep. Tr. at 141: 8 – 21</i>
(b) Mean C_{max} of less than about 90 ng/ml , and	YES	Figure 6 of GSK's '798 patent discloses a mean C_{max} of about 85 ng/ml .
(c) Mean AUC_{0-120h} of more than about 350 (ng-h)ml .	YES	Figure 6 of GSK's '798 patent discloses a mean AUC_{0-120h} of about 560 (ng-h)ml .

The Andrx '708 Patent Specification Limits the Dosage Form Structure to Pellets

SUMMARY OF THE PRESENT INVENTION



The Andrx '708 Patent Specification Limits the Dosage Form Structure to Pellets

DETAILED DESCRIPTION OF THE PRESENT INVENTION

US 6,905,704 B2

adhesive (Bondwell) following a single oral dose of the formulation in Example 1 versus 150 mg of the commercially available sustained release product (Zytac®).

INITIAL LED DESCRIPTION OF THE PRISON

The present invention, in a first embodiment, provides a two-component arrayed system comprising a first cell line and a second cell line, the second cell line comprising

- (3) a dye patch comprising:
(a) a color comprising:
(i) a mixture of all blue, green, or a fluorescent
ultra-violet substances in proportion equal
to the blue patch is a strong absorbent red

- (d) a lubricant, and
(e) a swelling or expanding agent.

- (c) a cross-comparison:
- (i) hyphae and its soma, isotone, or a plasma-membranally vacuolated amoebocyte, or a developing germ, (ii) an insect pupa as a starting material, and (iii) a blood cell.

- (d) a useful compound:
 - (i) a useful organic compound;
 - (ii) a water-soluble polymer;
 - (iii) a plasticizer; and
 - (iv) a reinforcing agent.

- The same idea: release divergences component may describe the form of immediate release heparin. This may be a form of immediate release.

also the kernel element properties to generate may, comprise (independent active paths) 0, (inactivated), may include (independent) gain paths coupled with a highly soluble (non-saturating, such as an Openly 50 type) coating, or those skilled in the art (e.g., generally, U.S. Pat. 7,127, or a combination of any of the foregoing).

The activities of large-scale hydroelectric plants, the present limitations on gradual water pricing having a very limiting effect on any complete use of economically known potential, which may be water available, and limited by a few spheres of access to the water available, such as, but not limited to, an

upland heron, a fisher, jumping, fish, about 1 m/s, probability ranging from about 50 to 80. The probability of getting a landing was still a factor depending on how close they were (62.5 percent if they were 51.5 percent of capture). The upland heron had a high density, low mobility, and low risk of capture.

The next forming heart component is collagen, which then comprises the primary structural material of the heart wall. Collagen is a protein that is secreted by the cells of the heart wall and is a major component of the extracellular matrix. It is a long, fibrous protein that is secreted by the cells of the heart wall and is a major component of the extracellular matrix. It is a long, fibrous protein that is secreted by the cells of the heart wall and is a major component of the extracellular matrix.

and should possess high efficiency and a capacity to generate good adherent bone tissue and bonyon particles, resulting in a

system of drug is the polymer. The binding system employed in this study is a blend of an apolar monomer (styrene) in the form of a polymerized polystyrene, hydroxyethyl cellulose (hydroxyethyl cellulose), low molecular weight hydroxyacetate and hydroxybutyrate (HHPAC), polyvinylpyrrolidone (PVP), cellulose, in a preferred combination of the previous formulation, the binding agent is a water-soluble polymer such as hydroxyacetate and polyvinylpyrrolidone having a molecular weight of 2–12 g/mol at 20 °C, preferably 4–6 g/mol, and as the component solvent, Methocel K100, K100, and polyvinylpyrrolidone.

The universal lens of the camera invention will probably continue for a long time, because:

Characteristic	Prevalence (%)	Mean \pm Standard Deviation
Age group (years)	44.44	45.17
Gender	75.56	75.56
Living status	22.22	22.22

This article pertains to you, in the provision of the product. It is not a contract, but it is a statement of the company's policy.

By figuring a suspension out for his binder and the flag, and then having the suspension enter the stage through using any of the layering techniques known in the industry, such as linked and nesting, your guarantee is performing. The suspension method may overcome any low visibility problem, such as improper lighting, closed, under, or stage, closed and so on. An American amount of suspension is provided the desired level of suspension. These methods can be used directly as the first component of the three components of the system of the same. A suspension.

Alternatively

into tablets b
percent of a

percent of a s
excipient tha

without crush

mixture in a s

Grant. The projected recapitalization in 2-1992 will change debt, and most probably equity.

[illegible][illegible][illegible]

dosage form

st adding fro

pharmaceut
form a com

the pellets, a

able tablet pr

the principal activities of my book is the author

7,708 412

the results in a number of instances, the respective statistical test is indicated by the number of columns, such as χ^2 , t , F , etc., and the application for the test is indicated in the text, such as *independent level analysis*, *linear regression*, etc.

The *comparisons* column lists the statistical test used and the *assumptions* column, of the particular statistical test, together in the *assumptions* and *comparisons* column, to indicate a related procedure. By entering the ratio of the *observed* frequency to the *expected* frequency, the *observed* frequency, including total of the *assumptions* column, is indicated in parentheses and the *assumptions* column is indicated in parentheses with the *assumptions* column.

The following examples are intended to illustrate the main question but are not intended to be exhaustive.

Exhibit 11

ulation may

m 25 to 40 w

Practically acceptable accessible minimum

compressible material
and then table

ess.


The authors thank Dr. J. K. Stillema for his helpful comments.

This work was supported by National Science Foundation Grant IBN-7908632.

Alternatively, the dosage formulation may be made into tablets by first adding from 25 to 40 weight percent of a solid pharmaceutically acceptable tablet excipient that will form a compressible mixture without crushing the pellets, and then tableting the mixture in a suitable tablet press.


The Andrx '708 Patent Specification Limits the Dosage Form Structure to Pellets

DETAILED DESCRIPTION OF THE PRESENT INVENTION




The Andrx '708 Patent Specification Limits the Dosage Form Structure to Pellets

EXAMPLE 1




The Andrx '708 Patent Specification Limits the Dosage Form Structure to Pellets

EXAMPLES 2 AND 3



The Andrx '708 Patent Specification Limits the Dosage Form Structure to Pellets

EXAMPLE 4



Georgia-Pacific Factors Analysis

FACTOR #1

FACTOR #1:

*Royalty Received
by Andrx
on '708 Patent*

EFFECT ON
ROYALTY RATE:

NO EFFECT

OBSERVATION:

- Andrx has **NEVER** licensed the '708 patent.

Source: Georgia-Pacific Corp. v. United States Plywood Corp., 318 F. Supp. 1116 (S.D.N.Y. 1970).

Georgia-Pacific Factors Analysis

FACTOR #2

FACTOR #2:

***Comparable
Rates Paid
by GSK***

EFFECT ON
ROYALTY RATE:

DECREASE



OBSERVATION:

PARTY

AGREEMENT

Biovail:

Agreement includes significant benefits to GSK beyond a naked patent license, thereby limiting its relevance to the determination of a reasonable royalty in a hypothetical negotiation.

**Skye
Pharma:**

Agreement to license a controlled release antidepressant formulation for ***3.0 to 4.0% of net sales*** plus an upfront fee of \$2 million and a “Back Payment” of \$10 million.

Source: *Georgia-Pacific Corp. v. United States Plywood Corp.*, 318 F. Supp. 1116 (S.D.N.Y. 1970).

Georgia-Pacific Factors Analysis

FACTOR #3

FACTOR #3:

Scope of the License

EFFECT ON
ROYALTY RATE:

NO EFFECT

OBSERVATION:

- Andrx attempted to make the product itself, which implies a non-exclusive license.
- GSK would not want to pay extra for an exclusive license since it already paid Biovail for a de facto exclusive license.
- Neither GSK nor Andrx would wish the license to be restricted in any way since it is in both parties' interests to have GSK sell Wellbutrin XL[®] to as many customers as possible.

Source: Georgia-Pacific Corp. v. United States Plywood Corp., 318 F. Supp. 1116 (S.D.N.Y. 1970).

Georgia-Pacific Factors Analysis

FACTOR #4

FACTOR #4:

***Andrx's
Established
Licensing Policy***

EFFECT ON ROYALTY RATE:

DECREASE



OBSERVATION:

- Andrx 2005 Annual Report clearly states it seeks agreements with third parties to leverage its formulation capabilities and controlled release technologies.
- In 2004, Andrx generated almost \$50 million in licensing revenues which represents more than 70% of its net income in that year.

Source: Georgia-Pacific Corp. v. United States Plywood Corp., 318 F. Supp. 1116 (S.D.N.Y. 1970).

Georgia-Pacific Factors Analysis

FACTOR #5

FACTOR #5:

***Andrx/GSK
Relationship***

EFFECT ON
ROYALTY RATE:

DECREASE



OBSERVATION:

- Andrx does not sell a product based on a once-a-day bupropion formulation.
- Andrx's attempts at producing a once-a-day bupropion product were unsuccessful.
- The relationship between GSK and Andrx is one of inventor and promoter.

Source: *Georgia-Pacific Corp. v. United States Plywood Corp.*, 318 F. Supp. 1116 (S.D.N.Y. 1970).

Georgia-Pacific Factors Analysis

FACTOR #6

FACTOR #6:

Wellbutrin XL[®]
Effect on Sales
of Related
Products

EFFECT ON ROYALTY RATE:

DECREASE



OBSERVATION:

- No other products are associated with the sale of Wellbutrin XL[®].
- When Wellbutrin XL[®] launched in 2003, 50% of its sales came at the expense of Wellbutrin SR[®].
- In February 2004, 39% of Wellbutrin XL[®] sales came from Wellbutrin SR[®].

GSKAND026903, GSKAND028734

Source: Georgia-Pacific Corp. v. United States Plywood Corp., 318 F. Supp. 1116 (S.D.N.Y. 1970).

Georgia-Pacific Factors Analysis

FACTOR #7

FACTOR #7:

Term of the License

EFFECT ON
ROYALTY RATE:

DECREASE



OBSERVATION:

- As of the hypothetical negotiation date, the '708 patent had more than 17 years of patent life remaining.
- Long term licenses tend to have lower rates so as not to provide incentives to design around the patented technology.

Source: *Georgia-Pacific Corp. v. United States Plywood Corp.*, 318 F. Supp. 1116 (S.D.N.Y. 1970).

Georgia-Pacific Factors Analysis

FACTOR #8

FACTOR #8:

***Commercial
Success***

EFFECT ON
ROYALTY RATE:

INCREASE



OBSERVATION:

- Wellbutrin XL® allowed GSK to extend the Wellbutrin® brand beyond Wellbutrin SR®.
- Wellbutrin XL® has been a commercial success for GSK.
- Wellbutrin XL® has been unaffected by Wellbutrin SR® generics due to its superior clinical profile.

GSKAND028594, GSKAND028742

Source: Georgia-Pacific Corp. v. United States Plywood Corp., 318 F. Supp. 1116 (S.D.N.Y. 1970).

Georgia-Pacific Factors Analysis

FACTORS #9 and #10

FACTORS #9 and #10:

***Utility, Nature,
Benefits and
Advantages of
the '708 Patent***

EFFECT ON ROYALTY RATE:

INCREASE



OBSERVATION:

- Wellbutrin XL® provides an advantage over Wellbutrin SR® and other twice-daily antidepressant formulations
 - Increases patient compliance
 - Decreases probability that the medication will interrupt a patient's sleep cycle
- Side effects are reduced due to steadier plasma drug level throughout the day

GSKAND012061, GSKAND011672

Source: Georgia-Pacific Corp. v. United States Plywood Corp., 318 F. Supp. 1116 (S.D.N.Y. 1970).

Georgia-Pacific Factors Analysis

FACTOR #11

FACTOR #11:

***Extent of GSK's
Use of the
'708 Invention***

EFFECT ON ROYALTY RATE:

INCREASE



OBSERVATION:

- GSK utilized Wellbutrin XL[®] to extend its Wellbutrin[®] brand beyond Wellbutrin SR[®].
- Based on actual and projected GSK sales data, the company anticipates it will have sold more than \$1 billion of accused product as of the trial date.
- In 2005, Wellbutrin XL[®] accounted for approximately 4% of GSK's worldwide profits.

Source: *Georgia-Pacific Corp. v. United States Plywood Corp.*, 318 F. Supp. 1116 (S.D.N.Y. 1970).

Georgia-Pacific Factors Analysis

FACTOR #12

FACTOR #12:

***Customary
Royalty Rates
in the Industry***

EFFECT ON ROYALTY RATE:

DECREASE



OBSERVATION:

- Review of 10 licensing agreements involving controlled release pharmaceuticals.
 - 5 were instances of large pharmaceutical companies licensing a controlled release technology from a smaller development and/or generic pharmaceutical company.
 - 1 agreement specifically relates to GSK licensing a controlled release antidepressant formulation from Skye Pharma.
- Conclusion: A starting point for a hypothetical negotiation would range from 1% to 10% with a strong influence toward a more defined range of 2.8% to 4.6%.

Source: *Georgia-Pacific Corp. v. United States Plywood Corp.*, 318 F. Supp. 1116 (S.D.N.Y. 1970).

Georgia-Pacific Factors Analysis

FACTOR #14

FACTOR #14:

*The Opinion
of Qualified
Experts*

EFFECT ON
ROYALTY RATE:

NO EFFECT

OBSERVATION:

- To date I have considered the expert report of Scott Hampton.

Source: Georgia-Pacific Corp. v. United States Plywood Corp., 318 F. Supp. 1116 (S.D.N.Y. 1970).

Georgia-Pacific Factors Analysis

FACTOR #15

FACTOR #15:

***Willing Buyer/
Willing Seller
Hypothetical
Negotiation***

EFFECT ON ROYALTY RATE:

DECREASE



OBSERVATION:

- GSK and Andrx are assumed to have an understanding of each other's position.
- Hypothetical negotiation presumes the '708 patent is valid and infringed.
- Royalty rate must be such that both licensor and licensee are allowed to make reasonable expected economic profits.
- Georgia-Pacific analysis suggests a royalty rate at the mid to lower end of the initial range of 0.8% to 8.25%.

Source: Georgia-Pacific Corp. v. United States Plywood Corp., 318 F. Supp. 1116 (S.D.N.Y. 1970).

Georgia-Pacific Factors Analysis

	INITIAL RANGE BASED ON QUANTITATIVE FACTORS 0.08% TO 8.25%	
	GEORGIA-PACIFIC FACTOR	EFFECT
<i>Factors Tending to DECREASE Royalty Rate:</i>	Comparable rates paid by GSK	↓
	Andrx's established licensing policy	↓
	GSK/Andrx relationship	↓
	Wellbutrin XL® effect on sales of related products	↓
	Term of the license	↓
	Customary royalty rates in the industry	↓
	Portion of the Wellbutrin XL® profit credited to the '708 patent	↓
	Willing buyer/willing seller hypothetical negotiation	↓
<i>Factors Having NO EFFECT on Royalty Rate:</i>	Royalties received by Andrx on '708 patent	
	Scope of the license	
	Opinion of qualified experts	
<i>Factors Tending to INCREASE Royalty Rate:</i>	Commercial success of Wellbutrin XL®	↑
	Utility and advantages of the '708 patent	↑
	Nature and benefits of the '708 patent	↑
	Extent of GSK's use of the '708 invention	↑
CONCLUSION:	3.5% OF NET SALES WOULD BE A REASONABLE ROYALTY RATE	